Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

CEL-SCI Corp (CVM)

NYSE
Currency in USD
Disclaimer
1.470
-0.040(-2.65%)
Closed
After Hours
1.450-0.020(-1.361%)

CVM Comments

Approveal inckming Thur
To where
what happened?
Once FDA approval is obtained on Multikine, the share price is minimum $58 to a maximum of $110+, this is not taking into account any upward pressure from short squeeze. I am looooong from under $10.
Doesn't matter when holding for $20+
Go to 12!
Hard to see this stock on 15$
Jump in folks just pulled down 2,000 more shares it will bounce for sure!!
Any news gang ??
Dont panic
?
Is it time to buy ?
you were wrong bro
Did you buy?
Long time position. buy and hold and dont worry!
what just happened?
they reported the results of the study. Didn't meet the primary endpoint of the study of the therapy.
they reported the results of the study. Didn't meet the primary endpoint of the study of the therapy.
Looks like, trading halted...???
x10 bagger with the next 60 days.
when will the good news released and what time?
Price target?
60
Fly!!!
Tomorrow Green!!
it will go up to 40 before end of day
$80 by April 1, 2021
This is a $200 stock if Phase 3 is positive. Data is currently locked and phase 3 is imminent  Worthwhile taking a risk!!
over sold
approaching a new 52 week high
New 52 week high. Less than 7 day til July 1 Russell 3k
retesting the $8 resistance after July 1 Russell index volume and exposure will increase
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.